Recently, we showed that the BRCA1 promoter is frequently hypermethylated in ovarian cancer tissue, but the methylation status is often lost in recurrent disease, suggesting a potential resistance mechanism either through therapy‐induced cancer evolution or by clonal selection [10, 11, 12]. The gene discussed is BRCA1; the disease is cancer.